Funding Opportunities

• Pragmatic clinical trial on efficacy of managing reduced iron stores on risk of clinically important events in older adults with heart failure and anemia (U01 Clinical Trial Required)
  (PA-19-230)
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)
  (PAR-19-231)
  National Eye Institute
  Application Receipt Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Development of Sample Sparing Assays for Monitoring Immune Responses (U24 Clinical Trial Not Allowed)
  (RFA-AI-19-017)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): July 30, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
• Advancing Biomarker Discovery and Novel Point-of-Care Diagnostics for Active TB Disease Detection in HIV-1 Infected and Exposed Children (R01 Clinical Trial Optional)
  (RFA-AI-19-036)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): July 30, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
• Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required)
  (RFA-CA-19-035)
  National Cancer Institute
  Application Receipt Date(s): June 28, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• ITCR: innovative algorithms (R21 Clinical Trial Optional)
  (RFA-CA-19-038)
  National Cancer Institute
  Application Receipt Date(s): June 11, 2019; November 20, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
  (RFA-CA-19-039)
  National Cancer Institute
  Application Receipt Date(s): June 11, 2019; November 20, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
  (RFA-CA-19-040)
  National Cancer Institute
  Application Receipt Date(s): June 11, 2019; November 20, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
  (RFA-CA-19-041)
  National Cancer Institute
  Application Receipt Date(s): June 11, 2019; November 20, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Limited Competition: Follow-up on Subjects, Integrative Data Analysis and Measurement of Viral Antibodies in The Environmental Determinants of Diabetes in The Young Study (TEDDY) (U01 Clinical Trial Not Allowed)
  (RFA-DK-18-512)
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): June 03, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement.
• Renewal Application: Increasing the Quality and Efficiency of Clinical Trials (U18) Clinical Trial Required
  (RFA-FD-19-015)
  Food and Drug Administration
  Application Receipt Date(s): June 3, 2019, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Cooperative Agreement to Support the World Trade Organization's (WTO) Standards and Trade Development Facility (STDF) (U01 Clinical Trial Not Allowed)
  (RFA-FD-19-019)
  Food and Drug Administration
  Application Receipt Date(s): May 28, 2019 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Limited Competition Centers of Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEER) (RM1 Clinical Trial Optional)
  (RFA-HG-19-012)
  National Human Genome Research Institute
  Application Receipt Date(s): July 23, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
  (RFA-RM-19-007)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): September 20, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
• NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)
  (RFA-RM-19-008)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): September 13, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.